Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avastin Recommended For Breast Cancer Approval In Japan; Telaprevir Leads List Of Unanimous Recommendations

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Telaprevir and a metastatic breast cancer indication for Avastin (bevacizumab) were among the blanket recommendations for approval by the Second Subcommittee on New Drugs of Japan's Ministry of Health, Labor and Welfare announced late in the day Aug. 25. Avastin's recommendation came just a few weeks after the subcommittee had expressed doubts about the drug's efficacy
Advertisement

Related Content

Mitsubishi Tanabe Gains Premium Prices For Fingolimod And Telaprevir
Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan
Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan
Novo Ramps Up In China, Roche Downplays Branded Generics, GSK Talks Up Japan While Hitting "The Inflection Point": Emerging Markets Round Up (Part 2)
Genentech Restricts Population In Last-Ditch Bid To Keep Avastin's Breast Cancer Claim
Vertex Takes Early Lead In HCV Protease Inhibitor Sales
Vertex Takes Early Lead In HCV Protease Inhibitor Sales
Ilaris Diabetes, Cardiovascular Trials Are Unethical, Public Citizen Says
Will World's Largest HCV Population Have Access To Newest Treatments?
Advertisement
UsernamePublicRestriction

Register

SC078837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel